Table 3. Comparison of MCM6 and Ki-67 expression levels based on different histologic and prognostic features.

Estrogen Receptor

 Negative

17.0 (9.0–24.0)

38.5 (32.0–43.0)

 Positive

10.0 (8.0–16)

26.5 (20.5–34.0)

Progesterone Receptor

 Negative

19.0 (9.5–24.0)

37.0 (29.7–42.2)

 Positive

10.0 (8.0–19.0)

26.9 (20.5–33.5)

HER2/Neu

 Negative

11.0 (8.0–17.0)

28.5 (21.2–37.7)

 Positive

13.0 (9.0–20.0)

33.5 (24.0–41.0)

Molecular Subtypes

 Luminal A

9.0 (7.0–10.0)

24.0 (18.0–31.5)

 Luminal B

16.0 (14.0–20.7)

30.5 (23.6–44.3)

 HER2-enriched

15.0 (7.0–23.0)

39.0 (18.0–41.5)

 Triple Negative

19.0 (9.0–38.0)

38.5 (34.7–53.0)

Lymphovascular Invasion

 Negative

10.5 (7.2–18.7)

30.2 (17.2–46.1)

 Positive

12.0 (9.0–17.7)

30.5 (21.6–38.1)

Lymph node Involvement

 Negative

12.0 (8.0–20.0)

33.0 (20.5–45.0)

 Positive

12.0 (8.5–17.5)

27.0 (21.5–36.2)

Extra-nodal Extension

 Negative

11.5 (9.0–20.2)

31.0 (22.4–37.4)

 Positive

11.0 (7.5–17.0)

31.0 (22.0–37.5)

In-situ Carcinoma

 Negative

12.0 (7.0–19.5)

29.7 (15.7–42.6)

 Positive

12.0 (9.0–17.5)

30.5 (21.5–38.6)

Nuclear Grade

 I

–

–

 II

10.0 (7.5–16.0)

23.5 (17.0–30.5)

 III

13.0 (9.0–21.0)

34.0 (26.9–42.9)

Mitotic Rate

 I

10.0 (7.0–14.8)

23.8 (16.2–33.5)

 II

12.0 (9.0–16.0)

30.5 (23.1–41.5)

 III

15.0 (9.0–24.8)

36.5 (27.1–44.4)

Tubule Formation

 I

9.0 (5.0–10.0)

18.25 (9.5–29.87)

 II

12.0 (8.0–16.0)

26.0 (21.25–33.5)

 III

13.0 (9.0–24.0)

33.0 (23.0–42.5)

Overall Grade

 I

9.0 (5.0–10.0)

16.0 (10.2–26.0)

 II

11.0 (8.0–16.0)

25.5 (20.1–33.5)

 III

14.5 (9.0–22.5)

36.0 (28.5–45.0)